Century Therapeutics, Inc.
IPSC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IPSC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IPSC
Century Therapeutics, Inc. is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers, currently advancing its lead candidate CNTY-101 in clinical trials.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Century Therapeutics, Inc..
Century Therapeutics, Inc. is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers, currently advancing its lead candidate CNTY-101 in clinical trials.
- Century Therapeutics focuses on iPSC-derived cell therapies for autoimmune diseases and cancers [sec_mda · as of 2025-08-14].
- Lead product candidate CNTY-101 is in clinical development for autoimmune indications [sec_mda · as of 2025-08-14].
- As of June 30, 2026, the company reported cash and equivalents of $52.0M and a net loss of $34.5M for the quarter [sec].
- The company expects its cash runway to fund operations into the first quarter of 2029, based on assumptions that may change [sec_mda · as of 2026-03-12].
- Century Therapeutics continues to invest in its iPSC platform, manufacturing capabilities, and preclinical pipeline [sec_mda · as of 2025-08-14].
What works
- The company has a differentiated iPSC platform that enables scalable, off-the-shelf cell therapy production, potentially reducing manufacturing complexity [sec_mda · as of 2025-08-14].
- Lead candidate CNTY-101 is being evaluated in autoimmune diseases, a large and growing market with high unmet need [sec_mda · as of 2025-08-14].
- Cash runway extended into early 2029 via a $126.7M private placement in 2026, providing financial flexibility for ongoing trials [sec_mda · as of 2026-03-12].
What to weigh
- The company has no approved products and has incurred significant operating losses, with a net loss of $34.5M in Q2 2026 [sec].
- Clinical development of CNTY-101 is still early, with no marketed product and substantial regulatory and commercial risks ahead [sec_mda · as of 2026-03-12].
- Future capital requirements are uncertain and may necessitate additional financing, which could dilute existing shareholders [sec_mda · as of 2025-08-14].
- The company faces intense competition from other cell therapy developers and traditional biologics in autoimmune and oncology spaces [sec_mda · as of 2026-03-12].
From the filings
Quoted directly from source documents.
The company's cash runway extends into the first quarter of 2029.
“117.1 million, and the additional $126.7 million we received as net proceeds from our 2026 private placement, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the first quarter of 2029.”
SEC MD&A · March 12, 2026
The company is focused on iPSC-derived cell therapies for autoimmune diseases and cancers.
“cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening autoimmune diseases and cancers.”
SEC MD&A · August 14, 2025
The company expects expenses and operating losses to increase substantially.
“We anticipate that our expenses and operating losses will increase substantially over the foreseeable future.”
SEC MD&A · March 12, 2026
Risks & what to watch (4)›
Key risks
- No approved products — Century has no marketed products and relies on successful clinical development and regulatory approval [sec_mda · as of 2026-03-12].
- Significant operating losses — Net loss of $34.5M in Q2 2026; accumulated deficit likely substantial [sec].
- Need for additional financing — Future capital needs may require further fundraising, with potential dilution [sec_mda · as of 2025-08-14].
- Clinical and regulatory uncertainty — Early-stage trials face risks of delay, failure, or unfavorable regulatory outcomes [sec_mda · as of 2026-03-12].
What to watch
- Clinical data updates for CNTY-101 in autoimmune diseases [sec_mda · as of 2025-08-14].
- Progress of preclinical pipeline and new candidate nominations [sec_mda · as of 2025-08-14].
- Cash runway updates and any additional financing activities [sec_mda · as of 2026-03-12].
- Regulatory milestones and IND filings for new indications [sec_mda · as of 2025-08-14].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Century Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Century Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
18.1 months
D/E 0.24 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
69
Total value held
$228.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 17,754,430 | $40.1M |
| vanguard capital management llc | 11,372,408 | $25.7M |
| deep track capital, lp | 9,487,745 | $21.4M |
| commodore capital lp | 8,695,652 | $19.7M |
| rtw investments, lp | 8,695,652 | $19.7M |
| woodline partners lp | 6,086,956 | $13.8M |
| balyasny asset management l.p. | 5,017,733 | $11.3M |
| millennium management llc | 4,667,063 | $10.5M |
| spruce street capital lp | 4,059,054 | $9.2M |
| adage capital partners gp, l.l.c. | 3,789,538 | $8.6M |
Showing top 10 of 69 institutional holders of Century Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 6.7%
- Days to cover
- 6.3
- Shares short
- 10,289,543
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IPSC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Century Therapeutics, Inc.?
Century Therapeutics, Inc. is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers, currently advancing its lead candidate CNTY-101 in clinical trials.
What is Century Therapeutics, Inc.'s lead drug candidate?
Century Therapeutics, Inc.'s most advanced tracked candidate is cnty-101 (Phase 1) for Systemic Lupus Erythematosus; R/R CD19-Positive B-Cell Malignancies.
Who is the CEO of Century Therapeutics, Inc.?
Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics, Inc. (IPSC).
Where is Century Therapeutics, Inc. headquartered?
Century Therapeutics, Inc. (IPSC) is headquartered in Philadelphia, PA, United States.
What therapeutic areas does Century Therapeutics, Inc. focus on?
Century Therapeutics, Inc. develops therapies across Oncology, Immunology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.